Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · Incretin receptor agonists

Semaglutide — compound monograph

GLP-1 receptor agonist (acylated, long-acting). Approved. The Institute assesses 11 outcomes for this compound and grades the strongest at high certainty.

Document identifier
CEI-MN-001
Series
Compound monograph
Version
1.1
Published
16 Sep 2023
Last reviewed
16 Aug 2024
Next review
16 Aug 2026
Identifier
10.71829/cei.mono.1
Certainty
High
Cycle
2023 Q3

§1Identification and status

§1.1Nomenclature

Preferred name
Semaglutide
Compound class
GLP-1 receptor agonist (acylated, long-acting)
Assessment series
Incretin receptor agonists
Synonyms and codes
NN9535 · NNC0113-0217 · semaglutide (INN) · Ozempic (trade) · Wegovy (trade) · Rybelsus (trade)
Route as evaluated
Subcutaneous once weekly; oral once daily with a permeation enhancer (see separate monograph)

§1.2Chemistry

Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]

CAS registry number
910463-68-2
Molecular formula
C187H291N45O59
Average mass
4113.58
Monoisotopic mass
4111.10
ATC classification
A10BJ06 · A10BX16 (combination)

§1.3Sequence and structural notes

H-Aib-EGTFTSDVSSYLEGQAAK(γGlu-2×AEEA-C18 diacid)EFIAWLVRGRG-OH

A 31-residue analogue of human GLP-1(7-37). Alanine at position 8 is replaced by α-aminoisobutyric acid to resist dipeptidyl peptidase-4 cleavage; lysine at position 34 is replaced by arginine to direct acylation; lysine 26 carries a γ-glutamate spacer, two 8-amino-3,6-dioxaoctanoic acid units and an octadecanedioic (C18) diacid that mediates reversible albumin binding.

§1.4Assessment status

The Institute assesses Semaglutide across 11 indications and grades the strongest of them at high certainty. Holds a marketing authorisation for at least one indication in at least one jurisdiction.

Distribution of certainty ratingsShare of assessed outcomes at each certainty level.11assessed outcomes
HighModerateLowVery low
Figure 1. Distribution of certainty ratings across the 11 outcomes the Institute assesses for Semaglutide. A rating attaches to a specific population, comparator and outcome and does not transfer between them.

Table 1. Assessed outcomes for Semaglutide, ordered by certainty. Each row links to the per-indication evidence extract.

IndicationEffect as recordedCertaintyTrials
Atherosclerotic cardiovascular disease and cardiovascular risk reductionThree-point MACE hazard ratio 0.80 in adults with overweight or obesity and established cardiovascular disease without diabetesHigh2
Chronic kidney disease in type 2 diabetesComposite kidney outcome hazard ratio 0.76 in type 2 diabetes with chronic kidney diseaseHigh1
Obesity and overweight in adults−14.9 % body weight at 68 weeks with semaglutide 2.4 mg versus −2.4 % with placeboHigh5
Type 2 diabetes mellitus−1.5 to −1.8 % HbA1c at 30–56 weeks versus placebo; superior to dulaglutide 1.5 mg in a head-to-head comparisonHigh4
Heart failure with preserved ejection fraction and obesityKCCQ clinical summary score improvement of 7.8 points versus placebo at 52 weeksModerate2
Hypertension in the context of adipositySystolic blood pressure −6.2 mmHg versus −1.1 mmHg with placebo (STEP 1)Moderate2
Metabolic dysfunction-associated steatohepatitisResolution of steatohepatitis without worsening of fibrosis in 62.9 % versus 34.3 % with placebo at 72 weeksModerate1
Obesity in children and adolescents−16.1 % BMI at 68 weeks versus +0.6 % with placeboModerate1
Peripheral arterial disease with intermittent claudicationMaximum walking distance ratio to baseline 1.21 versus 1.08 with placebo at 52 weeksModerate1
Prediabetes and progression to type 2 diabetesReversion to normoglycaemia in 84.1 % of participants with prediabetes at baseline versus 47.8 % with placebo (STEP 1)Low2
Sarcopenia and lean-mass preservation during weight reductionApproximately 39 % of total mass lost was lean mass in the DXA substudyLow1
Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.